AST-120 (Kremezin) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease
Status:
RECRUITING
Trial end date:
2027-03-13
Target enrollment:
Participant gender:
Summary
The primary goal of this clinical trial is to evaluate the efficacy of AST-120 (Kremezin) in combination with standard care in reducing the levels of protein-bound uremic toxins (PBUTs), specifically indoxyl sulfate (IS) and p-cresyl sulfate (p-CS), in patients with acute kidney disease (AKD). The trial aims to assess whether AST-120 can prevent further renal deterioration and slow the progression from AKD to chronic kidney disease (CKD) by mitigating the accumulation of PBUTs. Additionally, the study will investigate the potential of AST-120 to reduce the risk of CKD-associated complications, including cardiovascular disease, by reducing PBUT levels in AKD patients.